Stock SRZN SURROZEN, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Surrozen, Inc.

Equities

SRZN

US86889P2083

Delayed Nasdaq
Other stock markets
 08:08:18 29/04/2024 pm IST 		5-day change 1st Jan Change
9 USD +0.22% Intraday chart for Surrozen, Inc. -2.70% -4.26%
10/04 Surrozen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
08/04 Surrozen Insider Bought Shares Worth $2,999,994, According to a Recent SEC Filing MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Surrozen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Surrozen Insider Bought Shares Worth $2,999,994, According to a Recent SEC Filing
MT
Surrozen, Inc. announced that it has received $17.500008 million in funding from The Column Group, LLC, Ra Capital Management, Inc.
CI
Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis
AQ
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043
AQ
Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules
AQ
Surrozen Provides Update on the Phase 1A Clinical Trial of SZN-043 in Healthy Volunteers and Patients with Cirrhosis
CI
Surrozen, Inc. announced that it expects to receive $17.549999 million in funding
CI
Surrozen, Inc. Appoints Charles Williams to the Concurrent Position of Chief Operating Officer
CI
Sector Update: Health Care Stocks Softer Late Thursday Afternoon
MT
Sector Update: Health Care Stocks Weaker Thursday Afternoon
MT
Surrozen to Stop Inflammatory Bowel Disease Clinical Trial; Shares Fall
MT
Surrozen Provides Corporate Update on Clinical Programs
AQ
Surrozen, Inc. Provides Corporate Update on Clinical Programs
CI
Surrozen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Surrozen Provides Third Quarter 2023 Financial Results
AQ
Surrozen, Inc. Expects to Initiate A Phase 1a Clinical Trials for SZN-043 and SZN-1326 in Moderate to Severe Alcoholic Hepatitis
CI
Surrozen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Surrozen Provides Second Quarter 2023 Financial Results
AQ
Surrozen, Inc. Announces Management Changes
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SRZN Stock
  4. News Surrozen, Inc.